High-dose Intravenous Vitamin C in Patients With Septic Shock
Status:
Recruiting
Trial end date:
2022-12-22
Target enrollment:
Participant gender:
Summary
Despite promising observational and phase 1 data, the therapeutic potential of vitamin C for
the management of septic shock has not borne out in recent large multi-centre randomized
controlled trials. There is biological plausibility for benefit with intravenous vitamin C,
and the investigators hypothesize that the doses used in these trials were insufficient to
demonstrate an effect. High-dose vitamin C has been trialed in patients with cancer and burns
and proven to be safe. The investigators have recently demonstrated a dramatic benefit of
high-dose intravenous vitamin C in reversing organ dysfunction in a large mammalian model of
sepsis. The proposed prospective interventional study will be the first to administer
high-dose intravenous vitamin C in critically ill patients with sepsis. The objectives of
this study will be to determine whether high-dose intravenous vitamin C (i) reduces
vasopressor requirement in critically ill patients with septic shock (ii) reverses organ
dysfunction and (iii) is well tolerated.
Phase:
Phase 1
Details
Lead Sponsor:
Melbourne Health
Collaborators:
Monash Medical Centre The Florey Institute of Neuroscience and Mental Health University of Melbourne